Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease

British Journal of Cancer

Volumn 104, Issue 4, 2011, Pages 629-634

  Kang, B H ^a,e   Tavecchio, M ^a,b   Goel, H L ^a,c   Hsieh, C C ^a,c   Garlick, D S ^a,c   Raskett, C M ^a,c   Lian, J B ^a,c   Stein, G S ^a,c   Languino, L R ^a,d   Altieri, D C ^a,b  

^a Prostate Cancer Discovery and Development Program   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Ulsan National Institute of Science and Technology   (South Korea)

Author keywords

Hsp90; metastasis; mitochondria; prostate cancer; TRAMP

Indexed keywords

CYTOCHROME C; GAMITRINIB; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CYTOSOL; DRUG EFFICACY; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MEMBRANE POTENTIAL; METASTASIS; MITOCHONDRION; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; WEIGHT REDUCTION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GUANIDINES; HSP90 HEAT-SHOCK PROTEINS; LACTAMS, MACROCYCLIC; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS;

EID: 79951673830     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.9     Document Type: Article

References (36)

1. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434: 658-662 (Pubitemid 40488559)
2. Butcher EC (2005) Can cell systems biology rescue drug discovery? Nat Rev Drug Discov 4: 461-467 (Pubitemid 40861988)
3. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, Trock BJ, Metter EJ (2006) Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98: 1521-1527 (Pubitemid 44680903)
4. Chiaverotti T, Couto SS, Donjacour A, Mao J-H, Nagase H, Cardiff RD, Cunha GR, Balmain A (2008) Dissociation of epithelial and neuro-endocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 172: 236-246 (Pubitemid 351186384)
5. Drysdale MJ, Brough PA (2008) Medicinal chemistry of Hsp90 inhibitors. Curr Top Med Chem 8: 859-868 (Pubitemid 351984709)
6. Ghosh JC, Siegelin MD, Dohi T, Altieri DC (2010) Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res 70: 8988-8993
7. Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305: 626-629 (Pubitemid 39006738)
8. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92: 3439-3443
9. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G (2008) A phase II trial of 17-allylamino-17-demethoxygeldana-mycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940-7946
10. Hsieh CL, Xie Z, Yu J, Martin WD, Datta MW, Wu GJ, Chung LW (2007) Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. The Prostate 67: 685-691 (Pubitemid 46709437)
11. Hua G, Zhang Q, Fan Z (2007) Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J Biol Chem 282: 20553-20560 (Pubitemid 47100029)
12. Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, Smith GJ (2007) Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia 9: 938-950 (Pubitemid 350086439)
13. Kang BH, Plescia J, Dohi T, Rosa J, Doxsey SJ, Altieri DC (2007) Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131: 257-270 (Pubitemid 47576138)
14. Kang BH, Plescia J, Song HY, Meli M, Colombo G, Beebe K, Scroggins B, Neckers L, Altieri DC (2009) Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 119: 454-464
15. Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, Dohi T, Lian JB, Stein GS, Languino LR, Altieri DC (2010) Preclinical characterization of mitochondria-directed, small molecule Hsp90 inhibitors, Gamitrinibs, in advanced prostate cancer. Clin Cancer Res 16: 4779-4788
16. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenberg NM (2003) Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 55: 219-237 (Pubitemid 36532401)
17. Kelland LR (2004) Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40: 827-836 (Pubitemid 38519761)
18. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, Trepel JB (2009) Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9: 1479-1492
19. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935 (Pubitemid 44497995)
20. Leav I, Plescia J, Goel HL, Li J, Jiang Z, Cohen RJ, Languino LR, Altieri DC (2010) Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 176: 393-401
21. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase i dose-escalation study. J Clin Oncol 25: 5410-5417 (Pubitemid 350232217)
22. Montesano Gesualdi N, Chirico G, Pirozzi G, Costantino E, Landriscina M, Esposito F (2007) Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 10: 342-350 (Pubitemid 350125789)
23. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y (2005) Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434: 652-658 (Pubitemid 40488558)
24. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL (2008) The current state of preclinical prostate cancer animal models. Prostate 68: 629-639 (Pubitemid 351614641)
25. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, Humphrey PA, Sundberg JP, Rozengurt N, Barrios R, Ward JM, Cardiff RD (2004) Prostrate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 64: 2270-2305 (Pubitemid 38339483)
26. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB (2008) Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res 14: 8302-8307
27. Sung S-Y, Hsieh C-L, Law A, Zhau HE, Pathak S, Multani AS, Lim S, Coleman IM, Wu L-C, Figg WD, Dahut WL, Nelson P, Lee JK, Amin MB, Lyles R, Johnstone PAJ, Marshall FF, Chung LWK (2008) Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res 68: 9996-10003
28. Taichman RS, Loberg RD, Mehra R, Pienta KJ (2007) The evolving biology and treatment of prostate cancer. J Clin Invest 117: 2351-2361 (Pubitemid 47494332)
29. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22
30. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549
31. Tse AN, Klimstra DS, Gonen M, Shah M, Sheikh T, Sikorski R, Carvajal R, Mui J, Tipian C, O'Reilly E, Chung K, Maki R, Lefkowitz R, Brown K, Manova-Todorova K, Wu N, Egorin MJ, Kelsen D, Schwartz GK (2008) A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17- demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res 14: 6704-6711
32. Voeks DJ, Martiniello-Wilks R, Russell PJ (2002) Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies. Urol Oncol 7: 111-118
33. Vogiatzi P, Cassone M, Claudio L, Claudio PP (2009) Targeted therapy for advanced prostate cancer: looking through new lenses. Drug News Perspect 22: 593-601
34. Walrath JC, Hawes JJ, Van Dyke T, Reilly KM (2010) Genetically engineered mouse models in cancer research. Adv Cancer Res 106: 113-164
35. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772 (Pubitemid 41400776)
36. Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE, Day ML (2007) 5-aza-2-deoxycytidine delays androgen-independent disease and improves model of prostate survival in the transgenic adenocarcinoma of the mouse prostate mouse cancer. Clin Cancer Res 13: 2136-2143 (Pubitemid 46649883)